# Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

> **NCT03344211** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Southern California** · enrollment: 30 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Prostate Carcinoma Metastatic in the Bone
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Radium Ra 223 Dichloride

## Key facts

- **NCT ID:** NCT03344211
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-21
- **Primary completion:** 2026-11-21
- **Final completion:** 2027-11-21
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344211, "Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03344211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*